**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 5508**

**Columns: TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (12): **Nonalcoholic fatty liver disease**

**Dietary habits and behaviors associated with nonalcoholic fatty liver disease**

Yasutake K *et al*.Nutritional strategy for NAFLD

Kenichiro Yasutake, Motoyuki Kohjima, Kazuhiro Kotoh, Manabu Nakashima, Makoto Nakamuta, Munechika Enjoji

**Kenichiro Yasutake,** Department of Health and Nutrition Sciences, Faculty of Health and Social Welfare Sciences, Nishikyushu University, Kanzaki 842-8585, Japan

**Motoyuki Kohjima, Makoto Nakamuta,** Department of Gastroenterology and Clinical Research Center, Kyushu Medical Center, National Hospital Organization, Fukuoka 810-8563, Japan

**Kazuhiro Kotoh,** Department of Hepatology and Pancreatology, Kyushu University Hospital, Fukuoka 812-8582, Japan

**Manabu Nakashima,** Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan

**Munechika Enjoji,** Health Care Center, Fukuoka University, Fukuoka 814-0180, Japan

**Author contributions:** Yasutake K and Enjoji M drafted the review; and all of the authors wrote the final version.

**Correspondence to:** **Munechika Enjoji, MD, PhD,** Health Care Center, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. enjoji@adm.fukuoka-u.ac.jp

**Telephone:** +81-92-8716631 **Fax:** +81-92-8630389

**Received:** September 11, 2013 **Revised:** November 11, 2013

**Accepted:** December 3, 2013

**Published online:**

**Abstract**

Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent causes of health problems in Western (industrialized) countries. Moreover, the incidence of infantile NAFLD is increasing, with some of these patients progressing to nonalcoholic steatohepatitis. These trends depend on dietary habits and life-style. In particular, overeating and its associated obesity affect the development of NAFLD. Nutritional problems in patients with NAFLD include excess intake of energy, carbohydrates, and lipids, and shortages of polyunsaturated fatty acids, vitamins, and minerals. Although nutritional therapeutic approaches are required for prophylaxis and treatment of NAFLD, continuous nutrition therapy is difficult for many patients because of their dietary habits and lifestyle, and because the motivation for treatment differs among patients. Thus, it is necessary to assess the nutritional background and to identify nutritional problems in each patient with NAFLD. When assessing dietary habits, it is important to individually evaluate those that are consumed excessively or insufficiently, as well as inappropriate eating behaviors. Successful nutrition therapy requires patient education, based on assessments of individual nutrients, and continuing the treatment. In this article, we update knowledge about NAFLD, review the important aspects of nutritional assessment targeting treatment success, and present some concrete nutritional care plans which can be applied generally.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Nonalcoholic fatty liver disease; Nutritional therapy; Carbohydrates; Fatty acids; Cholesterol

**Core tip:** The onset and development of nonalcoholic fatty liver disease (NAFLD) are closely associated with dietary habits and lifestyle; therefore, nutritional therapeutic approaches are required for these patients and those at risk of developing NAFLD. This article reviewed current nutritional status of NAFLD patients and the important aspects of nutritional assessment targeting treatment success.

Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M.Dietary habits and behaviors associated with nonalcoholic fatty liver disease.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Nonalcoholic fatty liver disease (NAFLD) is a major health problem in Western countries, affecting 30% of the adult population and 60%-80% of patients with diabetes mellitus and/or obesity[1,2]. The 2011 National Health and Nutrition Examination Survey reported that the rates of NAFLD, obesity, and type 2 diabetes have increased coordinately over time since the 1988–1994 survey[2], indicating that NAFLD is associated with obesity and type 2 diabetes.

In addition, the prevalence of NAFLD in children and adolescents is increasing, and has been reported to be about 10%[3-5]. Although genetic factors have been associated with the onset of pediatric NAFLD[6], the most important risk factor in children, as in adults, is overweight, with the prevalence of NAFLD higher in obese than in non-obese children[3,7-9]. Moreover, nonalcoholic steatohepatitis (NASH) has been diagnosed in 3% of children and adolescents[5].

About 20%-25% of adults with NASH have been reported to develop liver cirrhosis within 10 years[1], with hepatocellular carcinoma occurring in 8.6% of cirrhotic NASH patients within 12 years[10] or in 11.3% within 5 years[11]. A recent meta-analysis showed that, compared with patients with simple steatosis, those with NASH have higher liver-related mortality rates, with an odds ratio (OR) for patients with NASH of 5.71 and an OR for patients with NASH and advanced fibrosis of 10.06[12]. In addition, NAFLD is considered as a risk factor for cardiovascular disease (CVD), because many patients with NAFLD develop metabolic disorders[13]. A longitudinal study of 129 patients with biopsy-proven NAFLD who were followed for a mean of 13.7 years found that mortality from cardiovascular events was higher than liver-related mortality, with the overall mortality of patients with NASH being twice that of a matched reference population[14]. Similarly, a cohort study of Swedish patients with NAFLD who were followed-up for a mean of 28 years showed that mortality risks were higher for patients with NAFLD (OR 1.69) and NASH (OR 1.86), compared with the general Swedish population, and that CVD is the most frequent cause of death[15]. Another prospective, nested, case-control study in 2,103 patients with type 2 diabetes without diagnosed CVD at baseline who were followed-up for a mean 5 years found that the presence of NAFLD was significantly associated with an increased CVD risk (OR 1.84) and that this relationship was independent of classical risk factors[16].

Because NAFLD develops as early as childhood and was found to exacerbate other conditions and worsen patient prognosis, treatment methods are urgently needed. Nutrition therapy is the basic form of treatment for patients with NAFLD and those at risk of developing this disorder. Therefore, all clinical staff involved in NAFLD prevention or treatment should understand nutritional strategies for dealing with NAFLD.

**BEHAVIORAL SCIENCE AND MULTIDISCIPLINARY NUTRITIONAL CARE FOR SUCCESSFUL NUTRITION THERAPY**

NAFLD is closely associated with obesity. Put simply, obesity results from greater energy intake than consumption, with excessive energy accumulated as fat. NAFLD patients with excess energy intake have shown improvements following weight loss resulting from restricted energy intake; *e.g.*, 600-800 kcal/d, 25-30 kcal/kg (standard weight)/d, or baseline minus 500-1000 kcal/d (Table 1)[17-24]. Although restricted diets are clinically effective in the short-term, long-term energy and weight control is very difficult for many patients[25]. For example, a 6-mo nutritional intervention was successful in only 54.8% of patients with NAFLD[24], perhaps because patients differ in grade of motivation and preparation for the therapy.

Generally, a desirable health behavior is attained by changes that progress through five stages evaluated by the transtheoretical model: (1) a precontemplation stage, in which a patient has no intention of changing in the foreseeable future; (2) a contemplation stage, in which a patient intends to change, but not soon; (3) a preparation stage, in which a patient intends to change during the next month; (4) an action stage, in which a patient changes; and (5) a maintenance stage, in which a patient has maintains the change for at least 6 mo[[26](#_ENREF_24),27]. The transtheoretical model, a popular concept in the area of health psychology, has been applied in patients with smoking, obesity, Human immunodeficiency virus infection, and so on. The answers to the different questions are summed up to evaluate motivation to change according to the transtheoretical model of upper five stages of change, using 10 statements; two for each stage. The different stages of change have been theorized to predict treatment participation to programs and dropout, as well as efficacy and long-term maintenance of improvement. An evaluation of the intake of low-fat health food diets by obese patients with diabetes using these five stages found that 48.2% of male patients and 25.0% of female patients were at the precontemplation and contemplation stages[28,29]. This trend was similar in patients with NAFLD. Dietary habits and physical activity in NAFLD patients were reported to be associated with the stages of change evaluated by the transtheoretical model, in which highest 36.0% of patients were at the contemplation stages[30]. Therefore, although all NAFLD patients require nutrition therapy, more than 50% will not readily accept the need for or practice nutrition therapy. Thus, prior to initiating nutrition therapy, it is important to assess whether an individual patient is at a receptive stage for it. Behavioral counselors should therefore work flexibly with patients. For example, motivation by raising a patient’s consciousness level is important during the precontemplation stage. During the contemplation stage, it is necessary for the patient to evaluate the effects of behavior modification, strengthening each patient’s motivation and supporting his/her decision making. A recent randomized controlled trial in patients with NASH found that 48-week-long lifestyle intervention, using a combination of diet, exercise, and behavior modification, significantly improved patient histologic activity score, body weight, body mass index (BMI), and serum alanine aminotransferase (ALT) levels[31]. Patients discussed dietary and health problems during weekly group sessions, and their nutritional education employed several techniques of behavioral science, including self-monitoring of food eaten, body weight, and exercise; stimulus control techniques; and education to prevent relapse[31-33].

Similarly, in patients with pediatric NAFLD, a 6-mo-long lifestyle intervention, consisting of physical exercise, dietary counseling, and behavioral counseling, improved steatosis and serum ALT levels[34]. In another study on obese pediatric NAFLD patients, lifestyle intervention, consisting of physical activity, nutritional education, and behavioral therapy, for 1 year decreased BMI and serum ALT levels, with improvements maintained 1 year after the completion of this intervention[35]. Reductions in BMI and ALT not only improved the grade of NAFLD in these patients but prevented its progression to steatohepatitis[36]. These findings indicate that nutritional education employing behavioral methods conducted by a multidisciplinary nutritional care team is extremely useful and effective.

**ASSESSMENT OF THE MAIN CAUSE OF EXCESS ENERGY INTAKE**

For nutritional therapy to yield better outcomes, more detailed assessments of excess energy intake are needed. Some eating patterns are closely associated with excessive intake, such as increased dietary volume, high energy-dense diets, inappropriate mealtimes and manner of eating, and excessive intake of specific nutrients. It is important to determine the factor(s) crucial for each patient and to supply each patient with individual knowledge for appropriate dietary interventions.

***Increased dietary volume***

Increased dietary volume may be due to, for example, a high frequency of eating outside the home, larger food portions, and the diffusion of all-you-can-eat style. Energy intake during a meal is usually larger while eating out than while eating at home. Eating out was reported to increase overall energy intake by 14% in 1977-1978, a rate that increased to 32% during 1994-1996[37]. In addition, portion sizes of salty snacks, hamburger, soft drinks, fried potatoes, and Mexican food eaten outside the home in 1977-1978, 1989-1991, and 1994‒1998 increased over time in almost all examined subjects[38]. Enlarged meal volume increases energy intake, resulting in obesity and NAFLD[39]. Energy intake also tends to be higher at all-you-can-eat restaurants because various kinds of foods are displayed. Actually, an increase in the variety of dishes at a meal has been found to enhance food intake by at least 25%, because of the variety of sensory properties of the foods, such as taste, palatability, and flavor[40-43]. Food intake may be reduced by reducing the frequency of eating out and of eating at all-you-can-eat establishments. Moreover, when eating at home, the food/energy requirement in a meal should be habitually arranged beforehand, by, for example, the distribution of individual portions.

***High energy-dense diets***

Fast-foods, meals eaten out, and fried foods are representative of a high energy-dense diet. A study assessing the influence of fast-foods on liver function found that young adults with a daily energy intake of 2273 ± 558 kcal (fat: 36% ± 5.7%, sugar: 95 ± 42 g) given fast-food-based hyperalimentation of 5753±1495 kcal (fat: 43% ± 6.8%, sugar: 285 ± 117 g) for 4 wk showed an increase in body weight from 67.6 ± 9.1 to 74.0 ± 11.0 kg and an increase in serum ALT levels from 22.1 ± 11.4 to 97 ± 103 U/L[44]. These findings indicated that a high energy-dense diet can increase energy intake easily and markedly, resulting in obesity and NAFLD. In the CARDIO study, the habitual eating of fast-foods was assessed in young adults at baseline and 15 years later, and the association of a fast-food diet with weight gain and insulin resistance was analyzed[45]. A higher frequency of fast-foods at baseline and at the end of the 15-year follow-up resulted in greater weight gain, independent of race or ethnicity, with the frequency of eating fast-foods positively correlated with mean energy intake[45,46]. Official rules for the fast-food industry, such as energy restriction, increasing quantities of vegetables, and non-inclusion in children’s meals of toy lagniappes, have been introduced in several countries. Thus, prior to starting a patients with NAFLD on nutrition therapy, the frequency of eating fast-foods, fried foods, and eating out should be assessed beforehand. Decreasing all of these may prevent the development and/or progression of NAFLD. It is recommended that these individuals eat at home more frequently and that they consume a low energy-dense diet, with higher quantities of vegetables.

***Inappropriate mealtimes and eating manners***

Inappropriate patterns of food intake, including the habit of eating too much at evening meals, eating at night, missing breakfast, and eating too rapidly, are often seen in patients with obesity and NAFLD. The night-eating syndrome is frequently observed in obese patients[47]. Night workers and shift workers were recently shown to be at high risks of obesity, metabolic syndrome, and fatty liver disease[48-50]. Food intake at unusual times by shift workers induces chronic sleep disorder and increased desire for fats, resulting in obesity and diabetes[51]. This phenomenon may be due to the activity of the clock genes. Male Period gene-mutant mice gain significantly more body mass than wild-type controls on high-fat diet [52].

Missing breakfast, especially by children and adolescences, has been associated with obesity[53]. Missing breakfast usually increases food intake at other mealtimes. Mice with a greater energy intake in the evening meal had a higher body weight, more visceral fat, and higher fasting blood glucose levels, whereas all of these were lowest when the breakfast:evening meal energy ratio was 3:1[54]. Whenever possible, therefore, patients on nutrition therapy for NAFLD should be started on a diet in which energy intake in the evening and night-time is restricted and intake at breakfast should be enhanced. However, the problem of shift work cannot be resolved easily.

Individuals who eat more quickly eat more food and have a lessened feeling of satiety than those who eat more slowly (20‒30 chews per mouthful)[55]. Persons who eat faster have a higher mean BMI and an increased rate of BMI[56,57]. Increased mastication of each mouthful has been reported to prevent overeating and promote general and oral health[58]. Similarly, more than 20 chews per mouthful should be recommended during nutritional education for NAFLD patients to prevent overeating.

**OVER-INGESTION OF CARBOHYDRATES**

Carbohydrates are classified as simple and complex, with over-ingestion of simple carbohydrates, such as sucrose and fructose, being a major cause of NAFLD. Consumption of soft drinks, including those containing sucrose, is significantly increasing worldwide[59]. In comparison between NAFLD and non-NAFLD cases, mean daily consumption and mean frequency of soft drinks is at least two fold higher in patients with than without NAFLD[60-62]. The degree of ultrasonography-evaluated hepatic fatty changes was found to correlate with the increase in the number of consumed bottles of soft drinks, indicating that soft drink consumption is strongly predictive of fatty liver[62]. Moreover, the rates of consumption of simple and total carbohydrates were found to be higher in patients with NASH than in those with simple steatosis[17]. Excess intake of simple carbohydrates was found to rapidly induce elevated serum glucose levels and reactive hypoglycemia, resulting in a sensation of hunger, increasing appetite, and finally resulting in hyperphagia[63]. Excess intake of simple carbohydrates is closely associated with obesity and steatosis, perhaps through the activation of sterol regulatory element-binding protein-1c (SREBP-1c), a transcription factor that enhances the expression of enzymes associating with fatty acid synthesis[64].

The basic strategy in nutritional care is to understand each patient’s habits of consuming foods and soft drinks, including simple carbohydrates, and to restrict the intake of these foods and drinks, if excessive amounts have been ingested[65]. Restricting the intake of soft drinks requires patient motivation, although governments can also act by restricting these items. Taxation of soft drinks in the United States has been proposed to decrease their consumption and to provide revenue for national health programs[59,66,67].

In contrast, appropriate intake of complex carbohydrates, especially that of whole grains, may prevent the development and/or progression of NAFLD, because these grains contain antioxidative vitamins, minerals, and dietary fibers, in addition to carbohydrates[68]. Indeed, intake of whole grains may decrease visceral fat and improve obesity, dyslipidemia, and metabolic syndrome[69,70]. Moreover, a meta-analysis showed that whole grains reduced the risks of heart disease and type 2 diabetes; serum levels of fasting insulin, fasting glucose, and lipids; and body weight, all of which are associated with the pathogenesis of NAFLD[71-75]. Thus, paradoxically, a nutritional care plan for patients with NAFLD should seek to restrict carbohydrates, while increasing ingestion of whole grains.

**OVER-INGESTION OF LIPIDS**

Lipid over-ingestion results in excess energy intake and body fat accumulation. Increased visceral fat increase the inflow of free fatty acids into the liver, resulting in hepatic steatosis[76]. Over-ingestion of saturated fatty acids is thought to induce insulin resistance and type 2 diabetes[77-80]. A 7-day nutritional survey of diet showed that ingestion of saturated fatty acids was significantly greater in NAFLD patients than in healthy controls[81]. Moreover, intake of saturated fatty acids, as well as of lipids, was reported significantly greater in NAFLD and NASH patients than in healthy individuals[17]. When patients with NAFLD were randomly allocated an isoenergetic low-fat/low-saturated fat/low-glycemic index (GI) diet (LSAT: 23% fat/7% saturated fat/GI < 55) or a high-fat/high-saturated fat/high-GI diet (HSAT: 43% fat/24% saturated fat/GI >70), with liver fat quantitated by magnetic resonance spectroscopy before and after 4 weeks on the LSAT and HSAT diets, those in the LSAT, but not those in the HSAT group showed significant reductions in liver fat[82]. In other animal studies, a high-fat diet induced hepatic steatosis and inflammation, insulin resistance, and tumor necrosis factor α (TNFα) elevation[83-85]. These changes may be associated with the activation of peroxisome proliferators-activated receptor γ (PPARγ)[64].

Thus, over-ingestion of lipids, especially saturated fatty acids, is one of the most important risk factors for NAFLD onset and development. Therefore, before addressing NAFLD, it is recommended that patients’ eating habits be assessed, including patient intake of dairy products; fats in meat, butter and margarine; chocolate, and snack foods. If any of these foods are consumed excessively, its quantity should be reduced. Clinically, more concrete nutritional care plans are necessary; *e.g.*, bacon and sirloin, which contain considerable quantities of fat, should be switched to leg meat, fillet, or, if appropriate, to fish containing polyunsaturated fatty acids (PUFAs); and butter and margarine should be switched to the calorie-half products.

**OVER-INGESTION OF CHOLESTEROL**

Over-ingestion of cholesterol has been regarded as a critical cause of NAFLD[86-89]. For example, a 7-d nutritional survey found that dietary cholesterol intake was significantly greater in NASH patients than in healthy subjects[81]. In addition, our investigation of the dietary records of obese and non-obese NAFLD patients found that cholesterol ingestion was significantly greater in NAFLD patients than in healthy controls[90]. Interestingly, non-obese NAFLD patients ingested more cholesterol than obese NAFLD patients[90], indicating that cholesterol intake is dietetically essential for NAFLD onset/progression independent of obesity. These findings are supported by animal experiments, in which a high-cholesterol diet within the normal energy range induced the onset of non-obese NAFLD in mice[91-93]. Although the mechanisms have not been determined, the hepatic metabolic products of cholesterol, oxysterols, are ligands of liver X receptor α, which activates SREBP-1c and the *de novo* synthesis of fatty acids[94,95]. Although several studies reported no significant differences in cholesterol intake levels between NAFLD patients and healthy subjects, those studies did not assess dietary records but used food frequency questionnaires[96,97]. Future studies are needed to assess cholesterol intake levels and the clinical effects of cholesterol restriction in larger populations of patients with NAFLD. Over-ingestion of dietary cholesterol should be suspected in non-obese patients with NAFLD, and their dietary intake of food high in cholesterol, such as eggs, fish eggs, liver, and cakes, should be assessed. Reduction of cholesterol intake has also been recommended to prevent the development of CVD, regardless of the presence of obesity[98,99].

**DEFICIENCY OF POLYUNSATURATED FATTY ACIDS**

PUFA intake is lower in patients with NAFLD than in healthy individuals, regardless of excessive lipid intake[17,81]. Moreover, we found that PUFA intake was significantly lower in non-obese than in obese NAFLD patients[90]. These findings suggest that dietary contents are unbalanced in patients with NAFLD and that PUFA deficiency is involved in the onset and progression of NAFLD. PUFAs can improve insulin sensitivity by decreasing hepatic TNFα, can repress fatty acid synthesis by negatively controlling SREBP-1c, and can enhance fatty acid oxidation by positively controlling PPARα[100,101]. In some studies in animal models, administration of n-3 PUFAs reduced liver fat and improved hepatic inflammation[102,103]. These results are supported by nutritional interventions in patients with NAFLD. Although saturated fatty acids increase the likelihood of NAFLD development, PUFAs may be beneficial for these patients. For example, treatment of NAFLD patients for 12 mo with 1 g/d of n-3 PUFAs decreased ultrasonography-detected liver fat[104]. Moreover, in a study of patients receiving diet therapy with or without 2 g/d n-3 PUFAs for 6 mo, those administrated n-3 PUFA showed greater decreases in liver fat[105,106]. Furthermore, an 8-wk-long, double blind, crossover trial of 4 g/d n-3 PUFA and placebo showed that the accumulated liver fat decreased significantly in the n-3 PUFA group[107]. In none of these studies did n-3 PUFA show any adverse effects. Moreover, n-3 PUFAs improved risk factors for CVD, including markers of insulin resistance and inflammation, as well as serum levels of ALT, lipids and glucose. Deliberate supplementation with PUFA, especially n-3 PUFA, may be an effective form of nutrition therapy in patients with NAFLD, and may also prevent CVD[108,109]. However, combination with appropriate energy intake is a prerequisite, with the basic nutritional approach consisting of increasing the frequency of eating n-3 PUFA-rich fish in place of meat containing high quantities of saturated fatty acids.

**DEFICIENCY OF VITAMIN E**

Progression from NAFLD to NASH is commonly explained by the two-hit theory[110], with oxidative stress considered as a second hit factor[111-113]. Intake of vitamin E has been reported deficient in NAFLD and NASH patients compared with healthy subjects[81,114]. Moreover, in children, vitamin E intake was negatively correlated with the grade of liver fat. Total peroxide level and oxidative stress index were found to be positively correlated, and total antioxidant status negatively correlated, with fibrosis scores in patients with NAFLD[115]. These results are supported by other studies, which found that serum markers of oxidative stress were independent prognostic indicators of hepatic fibrosis[116-118]. Patients with NAFLD and NASH require more vitamin E to counteract increases in oxidative stress. Even if NAFLD patients take amounts of vitamin E equivalent to those taken by healthy individuals, patients may experience a net shortage, with reduced serum levels. However, many foods with high vitamin E contents, including some oils and fats, liver, and fish eggs, also contain large amounts of cholesterol, and greater quantities of these foods are ingested by NAFLD patients than by healthy individuals[18]. Although vegetables, especially green and yellow vegetables, do not have high vitamin E contents, they are important sources of this nutrient. Because vegetable intake by NAFLD patients is generally reduced[18], NAFLD patients with vitamin E deficiency should ingest higher quantities of green and yellow vegetables.

Patients who have dietary compliance problems should be administered vitamin E supplements. High-dose vitamin E supplementation has been reported to lower serum ALT levels in patients with NAFLD[23], and a randomized control study of vitamin E supplementation for 2 years to NASH patients without diabetes found that histologic activity score improved in a significantly higher percentage of the vitamin E than of the placebo group (43% *vs* 19%, *P* = 0.001)[119], demonstrating that vitamin E has clinical antioxidative effects. However, administration of high amounts of vitamin E may induce cerebral vascular disease and increase all-cause mortality[120,121]. A recent meta-analysis found that vitamin E treatment for 2 years of patients with NAFLD improved histology score, but led to a deterioration in insulin resistance and an increase in serum triglyceride levels[12]. In the United States practice guideline for the diagonosis and management of NAFLD, (1) Vitamin E (α-tocopherol) administered at daily dose of 800 IU/ d improves liver histology in non-diabetic adults with biopsy-proven NASH and therefore it should be considered as a first-line pharmacotherapy for this patient population, and (2) Until further data supporting its effectiveness become available, vitamin E is not recommended to treat NASH in diabetic patients, NAFLD without liver biopsy, NASH cirrhosis, or cryptogenic cirrhosis. Thus, while vitamin E is an important nutrient that can improve disease activity in patients with NASH, it also has the potential to cause other clinical problems. Patients receiving high-dose vitamin E supplementation should be closely monitored. According to recent studies, supplementation of 300 mg/d vitamin E seems to be safe and effective even in patients with fibrosis and/or impaired fasting glucose[23,122,123].

**DEFICIENCY OF VITAMIN D**

Vitamin D plays an important part in the processes of inflammation and autoimmunity. Deficiencies in vitamin D can result in insulin resistance, metabolic syndrome, and NAFLD[124]. Many obese children ingest a high-energy diet with low vitamin and mineral content, and are not sufficiently exposed to sunlight[125]. For example, serum vitamin D levels were low in 55% of young Americans[126]. Rats fed a Westernized diet (WD: high-fat/high-fructose corn syrup) with vitamin D depletion (29% compared with controls) had significantly poorer liver fat, lobular inﬂammation, and NAFLD activity scores than rats fed a WD, a low-fat diet (LFD), or a LFD with vitamin D depletion[127]. In humans, deficiency of vitamin D has been correlated with the severity of NAFLD activity score and hepatic fibrosis[128], perhaps owing to the greater oxidative stress resulting from vitamin D deficiency[129]. Hepatic expression of vitamin D receptors, CYP2R1 and CYP 27A1, has been negatively correlated with the severity of steatosis, inflammation, and NAFLD score in patients with NAFLD[130].

Taken together, these findings indicate that excess energy intake accompanied by vitamin D deficiency enhances the onset and progression of NAFLD/NASH. Thus, the status of vitamin D intake and serum vitamin D levels should be ascertained prior to beginning nutritional therapy for NAFLD. Patients with vitamin D deficiency should ingest foods with a high vitamin D content, such as fishes and mushrooms, at least once per day.

**NUTRITIONAL THERAPY WITH PROBIOTICS**

Probiotics are live bacteria or foods containing them that may confer a health benefit on the host by regulating intestinal microbial flora. Intestinal microbial flora change with BMI and eating habits[131,132]. Alteration of the enteral environment by probiotics has been shown to improve the pathology of NAFLD[133,134]. In animal models, administration of probiotics had desirable clinical effects, including decreases in liver fat and serum ALT and lipid levels, and improvements in inflammation, liver fibrosis, oxidative stress, and insulin resistance[132-142]. Serum levels of ALT, malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE), and TNFα have been reported to be decreased in NAFLD patients administered probiotics (Lactobacillus acidophilus, bifidus, rhamnosus, plantarum, salivarius, bulgaricus, lactis, casei, breve mixed with prebiotic fructooligosaccharide and vitamins as B2, B12, B6, D3, C, and folate) for 2 mo [143]. In addition, the probiotic VSL#3 had beneficial effects on lipid peroxidation markers (MDA, 4-HNE) in NAFLD patients[144]. A randomized, double-blind, placebo-controlled clinical trial found that administration of probiotics (Lactobacillus bulgaricus and Streptococcus thermophiles) for 3 mo significantly decreased serum aspartate aminotransferase, ALT, and γ-glutamyl transpeptidase levels in patients with NAFLD[145], in good agreement with results in animal models. Probiotic treatment can be included in nutrition therapy for NAFLD. Future studies investigating the effects of probiotics on other outcomes in patients with NAFLD, such as inhibition of hepatic fat accumulation and inflammation, as well as studies investigating foods containing probiotics, such as yogurt and lactic acid drinks, are expected.

**CONCLUSION**

Because the onset and development of NAFLD are closely associated with dietary habits and lifestyle, nutritional therapeutic approaches are required for these patients and those at risk of developing NAFLD. This article reviewed current nutritional strategies and their effects and problems.

**REFERENCES**

1 **Ratziu V**, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. *J Hepatol* 2010; **53**: 372-384 [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008]

2 **Younossi ZM**, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clin Gastroenterol Hepatol* 2011; **9**: 524-530.e1; quiz e60 [PMID: 21440669 DOI: 10.1016/j.cgh.2011.03.020]

3 **Patton HM**, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. *J Pediatr Gastroenterol Nutr* 2006; **43**: 413-427 [PMID: 17033514 DOI: 10.4103/1319-3767.74476]

4 **Papandreou D**, Rousso I, Mavromichalis I. Update on non-alcoholic fatty liver disease in children. *Clin Nutr* 2007; **26**: 409-415 [PMID: 17449148 DOI: 10.1016/j.clnu.2007.02.002]

5 **Schwimmer JB**, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006; **118**: 1388-1393 [PMID: 17015527 DOI: 10.1542/peds.2006-1212]

6 **Younossi ZM**, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. *Hepatology* 2005; **42**: 665-674 [PMID: 16116632 DOI: 10.1002/hep.20838]

7 **Alisi A**, Manco M, Panera N, Nobili V. Association between type two diabetes and non-alcoholic fatty liver disease in youth. *Ann Hepatol* 2009; **8 Suppl 1**: S44-S50 [PMID: 19381124]

8 **Huang SC**, Yang YJ. Serum retinol-binding protein 4 is independently associated with pediatric NAFLD and fasting triglyceride level. *J Pediatr Gastroenterol Nutr* 2013; **56**: 145-150 [PMID: 22983378 DOI: 10.1097/MPG.0b013e3182722aee]

9 **Wiegand S**, Keller KM, Röbl M, L'Allemand D, Reinehr T, Widhalm K, Holl RW, Group AP-S, the German Competence Network A. Obese boys at increased risk for nonalcoholic liver disease: evaluation of 16,390 overweight or obese children and adolescents. *Int J Obes (Lond)* 2010; **34**: 1468-1474 [PMID: 20531349 DOI: 10.1038/ijo.2010.106]

10 **Krawczyk K**, Szczesniak P, Kumor A, Jasinska A, Omulecka A, Pietruczuk M, Orszulak-Michalak D, Sporny S, Malecka-Panas E. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH). *J Physiol Pharmacol* 2009; **60 Suppl 3**: 71-75 [PMID: 19996485]

11 **Yatsuji S**, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. *J Gastroenterol Hepatol* 2009; **24**: 248-254 [PMID: 19032450 DOI: 10.1111/j.1440-1746.2008.05640.x]

12 **Musso G**, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Med* 2011; **43**: 617-649 [PMID: 21039302 DOI: 10.3109/07853890.2010.518623]

13 **Angulo P**. Nonalcoholic fatty liver disease. *N Engl J Med* 2002; **346**: 1221-1231 [PMID: 11961152 DOI: 10.1056/NEJMra011775]

14 **Ekstedt M**, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006; **44**: 865-873 [PMID: 17006923 DOI: 10.1002/hep.21327]

15 **Soderberg C,** Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. *Hepatology* 2010; **51:** 595-602 [PMID: 20014114 DOI: 10.1002/hep.23314]

16 **Targher G**, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. *Diabetes* 2005; **54**: 3541-3546 [PMID: 16306373 DOI: 10.2337/diabetes.54.12.3541]

17 **Toshimitsu K**, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, Kawamura M, Ebihara K, Onji M. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. *Nutrition* 2007; **23**: 46-52 [PMID: 17140767 DOI: 10.1016/j.nut.2006.09.004]

18 **Shi L**, Liu ZW, Li Y, Gong C, Zhang H, Song LJ, Huang CY, Li M. The prevalence of nonalcoholic fatty liver disease and its association with lifestyle/dietary habits among university faculty and staff in Chengdu. *Biomed Environ Sci* 2012; **25**: 383-391 [PMID: 23026517 DOI: 10.3967/0895-3988.2012.04.002]

19 **Vajro P**, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. *J Pediatr* 1994; **125**: 239-241 [PMID: 8040771 DOI: 10.1016/S0022-3476(94)70202-0]

20 **Andersen T**, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. *J Hepatol* 1991; **12**: 224-229 [PMID: 2051001 DOI: 10.1016/0168-8278(91)90942-5]

21 **Palmer M**, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. *Gastroenterology* 1990; **99**: 1408-1413 [PMID: 2210247]

22 **Ueno T**, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. *J Hepatol* 1997; **27**: 103-107 [PMID: 9252081 DOI: 10.1016/S0168-8278(97)80287-5]

23 **Hasegawa T**, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. *Aliment Pharmacol Ther* 2001; **15**: 1667-1672 [PMID: 11564008 DOI: 10.1046/j.1365-2036.2001.01083.x]

24 **Elias MC**, Parise ER, de Carvalho L, Szejnfeld D, Netto JP. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. *Nutrition* 2010; **26**: 1094-1099 [PMID: 20022466 DOI: 10.1016/j.nut.2009.09.001]

25 **Bugianesi E**, Marzocchi R, Villanova N, Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. *Best Pract Res Clin Gastroenterol* 2004; **18**: 1105-1116 [PMID: 15561641 DOI: 10.1016/j.bpg.2004.06.025]

26 **Prochaska JO**, Velicer WF. The transtheoretical model of health behavior change. *Am J Health Promot* 1997; **12**: 38-48 [PMID: 10170434 DOI: 10.4278/0890-1171-12.1.38]

27 **Prochaska JO,** DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. *Psychotherapy* 1982; **19:** 276–88 [DOI: 10.1037/h0088437]

28 **Greene GW**, Rossi SR. Stages of change for reducing dietary fat intake over 18 months. *J Am Diet Assoc* 1998; **98**: 529-34; quiz 535-6 [PMID: 9597025 DOI: 10.1016/S0002-8223(98)00120-5]

29 **Vallis M**, Ruggiero L, Greene G, Jones H, Zinman B, Rossi S, Edwards L, Rossi JS, Prochaska JO. Stages of change for healthy eating in diabetes: relation to demographic, eating-related, health care utilization, and psychosocial factors. *Diabetes Care* 2003; **26**: 1468-1474 [PMID: 12716806 DOI: 10.2337/diacare.26.5.1468]

30 **Centis E**, Moscatiello S, Bugianesi E, Bellentani S, Fracanzani AL, Calugi S, Petta S, Dalle Grave R, Marchesini G. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. *J Hepatol* 2013; **58**: 771-777 [PMID: 23201248 DOI: 10.1016]

31 **Promrat K**, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010; **51**: 121-129 [PMID: 19827166 DOI: 10.1002/hep.23276]

32 **D'Zurilla TJ**, Goldfried MR. Problem solving and behavior modification. *J Abnorm Psychol* 1971; **78**: 107-126 [PMID: 4938262 DOI: 10.1037/h0031360]

33 **Collins RL**, Parks GA, Marlatt GA. Social determinants of alcohol consumption: the effects of social interaction and model status on the self-administration of alcohol. *J Consult Clin Psychol* 1985; **53**: 189-200 [PMID: 3998247 DOI: 10.1037//0022-006X.53.2.189]

34 **Koot BG**, van der Baan-Slootweg OH, Tamminga-Smeulders CL, Rijcken TH, Korevaar JC, van Aalderen WM, Jansen PL, Benninga MA. Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement. *Arch Dis Child* 2011; **96**: 669-674 [PMID: 21518734 DOI: 10.1136/adc.2010.199760]

35 **Reinehr T**, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. *Arch Dis Child* 2009; **94**: 437-442 [PMID: 19224892 DOI: 10.1136/adc.2008.143594]

36 **Nobili V**, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. *Hepatology* 2008; **48**: 119-128 [PMID: 18537181 DOI: 10.1002/hep.22336]

37 **Guthrie JF**, Lin BH, Frazao E. Role of food prepared away from home in the American diet, 1977-78 versus 1994-96: changes and consequences. *J Nutr Educ Behav* 2002; **34**: 140-150 [PMID: 12047838 DOI: 10.1016/S1499-4046(06)60083-3]

38 **Nielsen SJ**, Popkin BM. Patterns and trends in food portion sizes, 1977-1998. *JAMA* 2003; **289**: 450-453 [PMID: 12533124 DOI: 10.1001/jama.289.4.450]

39 **Ledikwe JH**, Ello-Martin JA, Rolls BJ. Portion sizes and the obesity epidemic. *J Nutr* 2005; **135**: 905-909 [PMID: 15795457]

40 **Bellisle F**, Le Magnen J. The structure of meals in humans: eating and drinking patterns in lean and obese subjects. *Physiol Behav* 1981; **27**: 649-658 [PMID: 7323168 DOI: 10.1016/0031-9384(81)90237-7]

41 **Rolls BJ**, Rowe EA, Rolls ET, Kingston B, Megson A, Gunary R. Variety in a meal enhances food intake in man. *Physiol Behav* 1981; **26**: 215-221 [PMID: 7232526 DOI: 10.1016/0031-9384(81)90014-7]

42 **Rolls BJ**, Rowe EA, Rolls ET. How sensory properties of foods affect human feeding behavior. *Physiol Behav* 1982; **29**: 409-417 [PMID: 7178247 DOI: 10.1016/0031-9384(82)90259-1]

43 **Berry SL**, Beatty WW, Klesges RC. Sensory and social influences on ice cream consumption by males and females in a laboratory setting. *Appetite* 1985; **6**: 41-45 [PMID: 3994354 DOI: 10.1016/S0195-6663(85)80049-0]

44 **Kechagias S**, Ernersson A, Dahlqvist O, Lundberg P, Lindström T, Nystrom FH. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. *Gut* 2008; **57**: 649-654 [PMID: 18276725 DOI: 10.1136/gut.2007.131797]

45 **Pereira MA**, Kartashov AI, Ebbeling CB, Van Horn L, Slattery ML, Jacobs DR, Ludwig DS. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. *Lancet* 2005; **365**: 36-42 [PMID: 15639678 DOI: 10.1016/S0140-6736(04)17663-0]

46 **Bowman SA**, Gortmaker SL, Ebbeling CB, Pereira MA, Ludwig DS. Effects of fast-food consumption on energy intake and diet quality among children in a national household survey. *Pediatrics* 2004; **113**: 112-118 [PMID: 14702458 DOI: 0.1542/peds.113.1.112]

47 **STUNKARD AJ**, GRACE WJ, WOLFF HG. The night-eating syndrome; a pattern of food intake among certain obese patients. *Am J Med* 1955; **19**: 78-86 [PMID: 14388031]

48 **Sookoian S**, Gemma C, Fernández Gianotti T, Burgueño A, Alvarez A, González CD, Pirola CJ. Effects of rotating shift work on biomarkers of metabolic syndrome and inflammation. *J Intern Med* 2007; **261**: 285-292 [PMID: 17305651 DOI: 10.1111/j.1365-2796.2007.01766.x]

49 **Wang XS**, Armstrong ME, Cairns BJ, Key TJ, Travis RC. Shift work and chronic disease: the epidemiological evidence. *Occup Med (Lond)* 2011; **61**: 78-89 [PMID: 21355031 DOI: 10.1093/occmed/kqr001]

50 **Lin YC,** Chen PC. Persistent Rotating Shift Work Exposure Is a Tough Second Hit Contributing to Abnormal Liver Function Among On-Site Workers Having Sonographic Fatty Liver. *Asia Pac J Public Health* 2012; [Epub ahead of print] [PMID: 23239752 DOI: 10.1038/gene.2011.74]

51 **Antunes LC**, Levandovski R, Dantas G, Caumo W, Hidalgo MP. Obesity and shift work: chronobiological aspects. *Nutr Res Rev* 2010; **23**: 155-168 [PMID: 20122305 DOI: 10.1017/S0954422410000016]

52 **Dallmann R**, Weaver DR. Altered body mass regulation in male mPeriod mutant mice on high-fat diet. *Chronobiol Int* 2010; **27**: 1317-1328 [PMID: 20653457 DOI: 10.3109/07420528.2010.489166]

53 **de Castro JM**. When, how much and what foods are eaten are related to total daily food intake. *Br J Nutr* 2009; **102**: 1228-1237 [PMID: 19650955 DOI: 10.1017/S0007114509371640]

54 **Fuse Y**, Hirao A, Kuroda H, Otsuka M, Tahara Y, Shibata S. Differential roles of breakfast only (one meal per day) and a bigger breakfast with a small dinner (two meals per day) in mice fed a high-fat diet with regard to induced obesity and lipid metabolism. *J Circadian Rhythms* 2012; **10**: 4 [PMID: 22587351 DOI: 10.1186/1740-3391-10-4]

55 **Andrade AM**, Greene GW, Melanson KJ. Eating slowly led to decreases in energy intake within meals in healthy women. *J Am Diet Assoc* 2008; **108**: 1186-1191 [PMID: 18589027 DOI: 10.1016/j.jada.2008.04.026]

56 **Sasaki S,** Katagiri A, Tsuji T, Shimoda T, Amano K. Self-reported rate of eating correlates with body mass index in 18-y-old Japanese women. *Int J Obes Relat Metab Disord* 2003; **27:** 1405-10 [PMID: 14574353 DOI: 10.1038/sj.ijo.0802425]

57 **Otsuka R**, Tamakoshi K, Yatsuya H, Murata C, Sekiya A, Wada K, Zhang HM, Matsushita K, Sugiura K, Takefuji S, OuYang P, Nagasawa N, Kondo T, Sasaki S, Toyoshima H. Eating fast leads to obesity: findings based on self-administered questionnaires among middle-aged Japanese men and women. *J Epidemiol* 2006; **16**: 117-124 [PMID: 16710080 DOI: 10.2188/jea.16.117]

58 **Christen AG**, Christen JA. Horace Fletcher (1849-1919): "The Great Masticator.". *J Hist Dent* 1997; **45**: 95-100 [PMID: 9693596]

59 **Brownell KD**, Farley T, Willett WC, Popkin BM, Chaloupka FJ, Thompson JW, Ludwig DS. The public health and economic benefits of taxing sugar-sweetened beverages. *N Engl J Med* 2009; **361**: 1599-1605 [PMID: 19759377 DOI: 10.1056/NEJMhpr0905723]

60 **Assy N**, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, Grosovski M. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. *Can J Gastroenterol* 2008; **22**: 811-816 [PMID: 18925303]

61 **Ouyang X**, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. *J Hepatol* 2008; **48**: 993-999 [PMID: 18395287 DOI: 10.1016/j.jhep.2008.02.011]

62 **Abid A**, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. *J Hepatol* 2009; **51**: 918-924 [PMID: 19765850 DOI: 10.1016/j.jhep.2009.05.033]

63 **Melanson KJ**, Westerterp-Plantenga MS, Saris WH, Smith FJ, Campfield LA. Blood glucose patterns and appetite in time-blinded humans: carbohydrate versus fat. *Am J Physiol* 1999; **277**: R337-R345 [PMID: 10444538]

64 **Yamazaki T**, Nakamori A, Sasaki E, Wada S, Ezaki O. Fish oil prevents sucrose-induced fatty liver but exacerbates high-safflower oil-induced fatty liver in ddy mice. *Hepatology* 2007; **46**: 1779-1790 [PMID: 17935225 DOI: 10.1002/hep.21934]

65 **Schulze MB**, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. *JAMA* 2004; **292**: 927-934 [PMID: 15328324 DOI: 10.1001/jama.292.8.927]

66 **Jacobson MF**, Brownell KD. Small taxes on soft drinks and snack foods to promote health. *Am J Public Health* 2000; **90**: 854-857 [PMID: 10846500]

67 **Powell LM**, Chaloupka FJ. Food prices and obesity: evidence and policy implications for taxes and subsidies. *Milbank Q* 2009; **87**: 229-257 [PMID: 19298422 DOI: 10.1111/j.1468-0009.2009.00554.x]

68 **Ross AB**, Godin JP, Minehira K, Kirwan JP. Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. *Int J Endocrinol* 2013; **2013**: 585876 [PMID: 23762052 DOI: 10.1155/2013/585876]

69 **McKeown NM**, Yoshida M, Shea MK, Jacques PF, Lichtenstein AH, Rogers G, Booth SL, Saltzman E. Whole-grain intake and cereal fiber are associated with lower abdominal adiposity in older adults. *J Nutr* 2009; **139**: 1950-1955 [PMID: 19726588 DOI: 10.3945/jn.108.103762]

70 **Katcher HI**, Legro RS, Kunselman AR, Gillies PJ, Demers LM, Bagshaw DM, Kris-Etherton PM. The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. *Am J Clin Nutr* 2008; **87**: 79-90 [PMID: 18175740]

71 **Ye EQ**, Chacko SA, Chou EL, Kugizaki M, Liu S. Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease, and weight gain. *J Nutr* 2012; **142**: 1304-1313 [PMID: 22649266 DOI: 10.3945/jn.111.155325]

72 **Mellen PB**, Walsh TF, Herrington DM. Whole grain intake and cardiovascular disease: a meta-analysis. *Nutr Metab Cardiovasc Dis* 2008; **18**: 283-290 [PMID: 17449231 DOI: 10.1016/j.numecd.2006.12.008]

73 **de Munter JS**, Hu FB, Spiegelman D, Franz M, van Dam RM. Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review. *PLoS Med* 2007; **4**: e261 [PMID: 17760498 DOI: 10.1371/journal.pmed.0040261]

74 **Nettleton JA**, McKeown NM, Kanoni S, Lemaitre RN, Hivert MF, Ngwa J, van Rooij FJ, Sonestedt E, Wojczynski MK, Ye Z, Tanaka T, Garcia M, Anderson JS, Follis JL, Djousse L, Mukamal K, Papoutsakis C, Mozaffarian D, Zillikens MC, Bandinelli S, Bennett AJ, Borecki IB, Feitosa MF, Ferrucci L, Forouhi NG, Groves CJ, Hallmans G, Harris T, Hofman A, Houston DK, Hu FB, Johansson I, Kritchevsky SB, Langenberg C, Launer L, Liu Y, Loos RJ, Nalls M, Orho-Melander M, Renstrom F, Rice K, Riserus U, Rolandsson O, Rotter JI, Saylor G, Sijbrands EJ, Sjogren P, Smith A, Steingrímsdóttir L, Uitterlinden AG, Wareham NJ, Prokopenko I, Pankow JS, van Duijn CM, Florez JC, Witteman JC, Dupuis J, Dedoussis GV, Ordovas JM, Ingelsson E, Cupples L, Siscovick DS, Franks PW, Meigs JB. Interactions of dietary whole-grain intake with fasting glucose- and insulin-related genetic loci in individuals of European descent: a meta-analysis of 14 cohort studies. *Diabetes Care* 2010; **33**: 2684-2691 [PMID: 20693352 DOI: 10.2337/dc10-1150]

75 **Mozaffarian D**, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. *N Engl J Med* 2011; **364**: 2392-2404 [PMID: 21696306 DOI: 10.1056/NEJMoa1014296]

76 **Pagano G**, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. *Hepatology* 2002; **35**: 367-372 [PMID: 11826410 DOI: 10.1053/jhep.2002.30690]

77 **Maron DJ**, Fair JM, Haskell WL. Saturated fat intake and insulin resistance in men with coronary artery disease. The Stanford Coronary Risk Intervention Project Investigators and Staff. *Circulation* 1991; **84**: 2020-2027 [PMID: 1934376 DOI: 10.1161/01.CIR.84.5.2020]

78 **Feskens EJ**, Loeber JG, Kromhout D. Diet and physical activity as determinants of hyperinsulinemia: the Zutphen Elderly Study. *Am J Epidemiol* 1994; **140**: 350-360 [PMID: 8059770]

79 **Marshall JA**, Bessesen DH, Hamman RF. High saturated fat and low starch and fibre are associated with hyperinsulinaemia in a non-diabetic population: the San Luis Valley Diabetes Study. *Diabetologia* 1997; **40**: 430-438 [PMID: 9112020 DOI: 10.1007/s001250050697]

80 **Vessby B**, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, Nälsén C, Berglund L, Louheranta A, Rasmussen BM, Calvert GD, Maffetone A, Pedersen E, Gustafsson IB, Storlien LH. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. *Diabetologia* 2001; **44**: 312-319 [PMID: 11317662 DOI: 10.1007/s001250051620]

81 **Musso G**, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Fagà E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. *Hepatology* 2003; **37**: 909-916 [PMID: 12668986 DOI: 10.1053/jhep.2003.50132]

82 **Utzschneider KM**, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft S. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. *Br J Nutr* 2013; **109**: 1096-1104 [PMID: 22849970 DOI: 10.1017/S0007114512002966]

83 **Ha SK**, Chae C. Inducible nitric oxide distribution in the fatty liver of a mouse with high fat diet-induced obesity. *Exp Anim* 2010; **59**: 595-604 [PMID: 21030787 DOI: 10.1538/expanim.59.595]

84 **Longato L**, Tong M, Wands JR, de la Monte SM. High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism. *Hepatol Res* 2012; **42**: 412-427 [PMID: 22176347 DOI: 10.1111/j.1872-034X.2011.00934.x]

85 **Schattenberg JM**, Galle PR. Animal models of non-alcoholic steatohepatitis: of mice and man. *Dig Dis* 2010; **28**: 247-254 [PMID: 20460919 DOI: 10.1159/000282097]

86 **Zelber-Sagi S**, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. *World J Gastroenterol* 2011; **17**: 3377-3389 [PMID: 21876630 DOI: 10.3748/wjg.v17.i29.3377]

87 **Musso G**, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. *Diabetologia* 2012; **55**: 885-904 [PMID: 22278337 DOI: 10.1007/s00125-011-2446-4]

88 **Papandreou D**, Karabouta Z, Rousso I. Are dietary cholesterol intake and serum cholesterol levels related to nonalcoholic Fatty liver disease in obese children? *Cholesterol* 2012; **2012**: 572820 [PMID: 22811894 DOI: 10.1155/2012/572820]

89 **Enjoji M**, Yasutake K, Kohjima M, Nakamuta M. Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. *Int J Hepatol* 2012; **2012**: 925807 [PMID: 22550592 DOI: 10.1155/2012/925807]

90 **Yasutake K**, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T, Takemoto R, Miyahara T, Harada N, Hayata F, Nakashima M, Enjoji M. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. *Scand J Gastroenterol* 2009; **44**: 471-477 [PMID: 19058085 DOI: 10.1080/00365520802588133]

91 **Kainuma M**, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, Terasawa K, Shimada Y. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. *J Gastroenterol* 2006; **41**: 971-980 [PMID: 17096066 DOI: 10.1007/s00535-006-1883-1]

92 **Matsuzawa N**, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. *Hepatology* 2007; **46**: 1392-1403 [PMID: 17929294 DOI: 10.1002/hep.21874]

93 **Wouters K**, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, Kerksiek A, van Kruchten R, Maeda N, Staels B, van Bilsen M, Shiri-Sverdlov R, Hofker MH. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. *Hepatology* 2008; **48**: 474-486 [PMID: 18666236 DOI: 10.1002/hep.22363]

94 **Higuchi N**, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. *Hepatol Res* 2008; **38**: 1122-1129 [PMID: 18684130 DOI: 10.1111/j.1872-034X.2008.00382.x]

95 **Nakamuta M**, Fujino T, Yada R, Yada M, Yasutake K, Yoshimoto T, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Enjoji M. Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease. *Int J Mol Med* 2009; **23**: 603-608 [PMID: 19360318]

96 **Cortez-Pinto H**, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? *Clin Nutr* 2006; **25**: 816-823 [PMID: 16677739 DOI: 10.1016/j.clnu.2006.01.027]

97 **Zelber-Sagi S**, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, Oren R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. *J Hepatol* 2007; **47**: 711-717 [PMID: 17850914 DOI: 10.1016/j.jhep.2007.06.020]

98 U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government Printing Office, December 2010, www.dietaryguidelines.gov

99 **Teramoto T**, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. *J Atheroscler Thromb* 2013; **20**: 517-523 [PMID: 23665881 DOI: 10.5551/jat.15792]

100 **Ghafoorunissa A**, Rajkumar L, Acharya V. Dietary (n-3) long chain polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats. *J Nutr* 2005; **135**: 2634-2638 [PMID: 16253960]

101 **Teran-Garcia M**, Adamson AW, Yu G, Rufo C, Suchankova G, Dreesen TD, Tekle M, Clarke SD, Gettys TW. Polyunsaturated fatty acid suppression of fatty acid synthase (FASN): evidence for dietary modulation of NF-Y binding to the Fasn promoter by SREBP-1c. *Biochem J* 2007; **402**: 591-600 [PMID: 17313375]

102 **Sekiya M**, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, Ishibashi S, Osuga J, Yamada N, Shimano H. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. *Hepatology* 2003; **38**: 1529-1539 [PMID: 14647064 DOI: 10.1053/jhep.2003.09028]

103 **Levy JR**, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. *Hepatology* 2004; **39**: 608-616 [PMID: 14999679 DOI: 10.1002/hep.20093]

104 **Capanni M**, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. *Aliment Pharmacol Ther* 2006; **23**: 1143-1151 [PMID: 16611275 DOI: 10.1111/j.1365-2036.2006.02885.x]

105 **Zhu FS**, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. *World J Gastroenterol* 2008; **14**: 6395-6400 [PMID: 19009658 DOI: 10.3748/wjg.14.6395]

106 **Spadaro L**, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. *Dig Liver Dis* 2008; **40**: 194-199 [PMID: 18054848 DOI: 10.1016/j.dld.2007.10.003]

107 **Cussons AJ**, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. *J Clin Endocrinol Metab* 2009; **94**: 3842-3848 [PMID: 19622617 DOI: 10.1210/jc.2009-0870]

108 **Iso H**, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S; JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. *Circulation* 2006; **113**: 195-202 [PMID: 16401768 DOI: 10.1161/CIRCULATIONAHA.105.581355]

109 **Yamagishi K**, Iso H, Date C, Fukui M, Wakai K, Kikuchi S, Inaba Y, Tanabe N, Tamakoshi A; Japan Collaborative Cohort Study for Evakuation of Cancer Risk Srudy Group. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. *J Am Coll Cardiol* 2008; **52**: 988-996 [PMID: 18786479 DOI: 10.1016/j.jacc.2008.06.018]

110 **Day CP**, James OF. Steatohepatitis: a tale of two "hits"? *Gastroenterology* 1998; **114**: 842-845 [PMID: 9547102 DOI: 10.1016/S0016-5085(98)70599-2]

111 **Albano E**, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. *Gut* 2005; **54**: 987-993 [PMID: 15951547 DOI: 10.1136/gut.2004.057968]

112 **Seki S**, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. *J Hepatol* 2002; **37**: 56-62 [PMID: 12076862 DOI: 10.1016/S0168-8278(02)00073-9]

113 **Begriche K**, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. *Mitochondrion* 2006; **6**: 1-28 [PMID: 16406828 DOI: 10.1016/j.mito.2005.10.004]

114 **Erhardt A**, Stahl W, Sies H, Lirussi F, Donner A, Häussinger D. Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). *Eur J Med Res* 2011; **16**: 76-78 [PMID: 21463986 DOI: 10.1186/2047-783X-16-2-76]

115 **Horoz M**, Bolukbas C, Bolukbas FF, Sabuncu T, Aslan M, Sarifakiogullari S, Gunaydin N, Erel O. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. *BMC Gastroenterol* 2005; **5**: 35 [PMID: 16283935]

116 **Koruk M,** Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. *Ann Clin Lab Sci* 2004; **34:** 57-62 [PMID: 15038668]

117 **Fierbinţeanu-Braticevici C**, Bengus A, Neamţu M, Usvat R. The risk factors of fibrosis in nonalcoholic steatohepatitis. *Rom J Intern Med* 2002; **40**: 81-88 [PMID: 15526543]

118 **Videla LA**, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quiñones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, Poniachik J. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. *Clin Sci (Lond)* 2004; **106**: 261-268 [PMID: 14556645 DOI: 10.1042/CS20030285]

119 **Sanyal AJ**, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010; **362**: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]

120 **Sesso HD**, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *JAMA* 2008; **300**: 2123-2133 [PMID: 18997197 DOI: 10.1001/jama.2008.600]

121 **Bjelakovic G,** Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. *Cochrane Database Syst Rev* 2008; (3):CD004183 [PMID: 18677777 DOI: 10.1002/14651858.CD004183.pub3]

122 **Sumida Y**, Naito Y, Tanaka S, Sakai K, Inada Y, Taketani H, Kanemasa K, Yasui K, Itoh Y, Okanoue T, Yoshikawa T. Long-term (& gt; =2 yr) efficacy of vitamin e for non-alcoholic steatohepatitis. *Hepatogastroenterology* 2013; **60**: 1445-1450 [PMID: 23933938 DOI: 10.5754/hge11421]

123 **Han Y,** Shi JP, Ma AL, Xu Y, Ding XD, Fan JG. Randomized vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. *Clin Drug Investig* 2013 [Epub ahead of print] [PMID: 24081374 DOI: 10.1007/s40261-013-0136-3]

124 **Alvarez JA**, Ashraf A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. *Int J Endocrinol* 2010; **2010**: 351385 [PMID: 20011094 DOI: 10.1155/2010/351385]

125 **Bradlee ML**, Singer MR, Qureshi MM, Moore LL. Food group intake and central obesity among children and adolescents in the Third National Health and Nutrition Examination Survey (NHANES III). *Public Health Nutr* 2010; **13**: 797-805 [PMID: 19772691 DOI: 10.1017/S1368980009991546]

126 **Smotkin-Tangorra M**, Purushothaman R, Gupta A, Nejati G, Anhalt H, Ten S. Prevalence of vitamin D insufficiency in obese children and adolescents. *J Pediatr Endocrinol Metab* 2007; **20**: 817-823 [PMID: 17849744 DOI: 10.1515/JPEM.2007.20.7.817]

127 **Roth CL**, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE, Kowdley KV. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. *Hepatology* 2012; **55**: 1103-1111 [PMID: 21994008 DOI: 10.1002/hep.24737]

128 **Manco M**, Ciampalini P, Nobili V. Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease. *Hepatology* 2010; **51**: 2229; author reply 2230 [PMID: 20513013 DOI: 10.1002/hep.23724]

129 **Wu CC**, Chang JH, Chen CC, Su SB, Yang LK, Ma WY, Zheng CM, Diang LK, Lu KC. Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. *Tohoku J Exp Med* 2011; **223**: 153-159 [PMID: 21350317 DOI: 10.1620/tjem.223.153]

130 **Barchetta I**, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, Silecchia G, Leonetti F, Fraioli A, Picardi A, Morini S, Cavallo MG. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. *Hepatology* 2012; **56**: 2180-2187 [PMID: 22753133 DOI: 10.1002/hep.25930]

131 **Ley RE**, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature* 2006; **444**: 1022-1023 [PMID: 17183309 DOI: 10.1038/4441022a]

132 **Ma X**, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. *J Hepatol* 2008; **49**: 821-830 [PMID: 18674841 DOI: 10.1016/j.jhep.2008.05.025]

133 **Iacono A**, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. *J Nutr Biochem* 2011; **22**: 699-711 [PMID: 21292470 DOI: 10.1016/j.jnutbio.2010.10.002]

134 **Kelishadi R**, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. *Hepat Mon* 2013; **13**: e7233 [PMID: 23885277 DOI: 10.5812/hepatmon.7233]

135 **Li Z**, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. *Hepatology* 2003; **37**: 343-350 [PMID: 12540784 DOI: 10.1053/jhep.2003.50048]

136 **Velayudham A**, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. *Hepatology* 2009; **49**: 989-997 [PMID: 19115316 DOI: 10.1002/hep.22711]

137 **Lee HY**, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, Paek KS, Lee Y, Park JH. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. *Biochim Biophys Acta* 2006; **1761**: 736-744 [PMID: 16807088 DOI: 10.1016/j.bbalip.2006.05.007]

138 **Esposito E,** Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. *J Nutr* 2009; **139:** 905-11 [PMID: 19321579DOI: 10.3945/jn.108.101808]

139 **Karahan N**, Işler M, Koyu A, Karahan AG, Başyığıt Kiliç G, Cırış IM, Sütçü R, Onaran I, Cam H, Keskın M. Effects of probiotics on methionine choline deficient diet-induced steatohepatitis in rats. *Turk J Gastroenterol* 2012; **23**: 110-121 [PMID: 22706738]

140 **Wang Y**, Xu N, Xi A, Ahmed Z, Zhang B, Bai X. Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet. *Appl Microbiol Biotechnol* 2009; **84**: 341-347 [PMID: 19444443 DOI: 10.1007/s00253-009-2012-x]

141 **Paik HD**, Park JS, Park E. Effects of Bacillus polyfermenticus SCD on lipid and antioxidant metabolisms in rats fed a high-fat and high-cholesterol diet. *Biol Pharm Bull* 2005; **28**: 1270-1274 [PMID: 15997112 DOI: 10.1248/bpb.28.1270]

142 **Yadav H**, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. *Nutrition* 2007; **23**: 62-68 [PMID: 17084593 DOI: 10.1016/j.nut.2006.09.002]

143 **Loguercio C**, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, Cartenì M. Gut-liver axis: a new point of attack to treat chronic liver damage? *Am J Gastroenterol* 2002; **97**: 2144-2146 [PMID: 12190198 DOI: 10.1111/j.1572-0241.2002.05942.x]

144 **Loguercio C**, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. *J Clin Gastroenterol* 2005; **39**: 540-543 [PMID: 15942443 DOI: 10.1097/01.mcg.0000165671.25272.0f]

145 **Aller R**, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. *Eur Rev Med Pharmacol Sci* 2011; **15**: 1090-1095 [PMID: 22013734]

**P-Reviewers:** Faintuch J, Fan JG, Gong ZJ **S-Editor:** Song XX **L-Editor: E-Editor:**

**Table 1 Effect of nutritional intervention on nonalcoholic fatty liver disease**

Ibw: Ideal body weight; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ChE: Choline esterase; TC: Total cholesterol; FPG: Fasting plasma glucose; TGF: Transforming growth factor; GGT: γ-glutamyl transpeptidase; HDL-C: High density lipoprotein-cholesterol; HOMA-IR: Homeostasis model assessment for insulin resistance; WHR: Waist-to-hip ratio.

Improved items

ALT, fatty change

fatty change

ALT

AST, ALT, ChE, TC, FPG
fatty change

ALT, TGF-β, fatty change
inflammation, fibrosis

ALT, GGT, HDL-C, HOMA-IR
WHR, fatty change, visceral fat

No. of cases

9

41

39

25

22

31

Study design

Balanced hypocaliric
diet, exercise

Very-low calorie diet

Weight reduction
(retrospective)

Diet (25 cal/kg·ibw),
exercise

Diet (add 300 mg/d
of α-tocopherol)

Diet (baseline minus
500-1000 cal/d)

Ref.

[19]

[20]

[21]

[22]

[23]

[24]

Duration

9-30 mo

4-23 mo

―

3 mo

12 mo

6 mo